Novaferon for COVID-19 Treatment Trial (NCTT-005)

PHASE3UnknownINTERVENTIONAL
Enrollment

385

Participants

Timeline

Start Date

March 25, 2021

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions
Covid19
Interventions
BIOLOGICAL

Novaferon

a novel recombinant antiviral protein drug

BIOLOGICAL

Placebo

Saline

Trial Locations (22)

Unknown

RECRUITING

Chiba Aoba Municipal Hospital, Chiba

RECRUITING

Kamagaya General Hospital, Chiba

RECRUITING

NHO Chiba Medical Center, Chiba

ACTIVE_NOT_RECRUITING

NHO Omuta National Hospital, Fukuoka

RECRUITING

NHO Kasumigaura Medical Center, Ibaraki

ACTIVE_NOT_RECRUITING

Tsukuba Medical Center Foundation Tsukuba Medical Center Hospital, Ibaraki

RECRUITING

Kokankai Nippon Kokan Hospital, Kanagawa

RECRUITING

Rakuwakai Otowa Hospital, Kyoto

RECRUITING

Okayama City General Medical Center Okayama City Hospital, Okayama

RECRUITING

Osaka Habikino Medical Center, Osaka

RECRUITING

Rinku General Medical Center, Osaka

RECRUITING

Sakai City Medical Center, Osaka

RECRUITING

Omi Medical Center, Shiga

ACTIVE_NOT_RECRUITING

NHO Utsunomiya Hospital, Tochigi

ACTIVE_NOT_RECRUITING

Japanese Red Cross Medical Center, Tokyo

ACTIVE_NOT_RECRUITING

Juntendo University Hospital, Tokyo

ACTIVE_NOT_RECRUITING

Nihon University Itabashi Hospital, Tokyo

ACTIVE_NOT_RECRUITING

Showa University East Hospital, Tokyo

RECRUITING

Showa University Hospital, Tokyo

RECRUITING

Tokyo Medical University Hachioji Medical Center, Tokyo

RECRUITING

Tokyo Shinagawa Hospital, Tokyo

RECRUITING

NHO Iwakuni Clinical Center, Yamaguchi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genova Inc.

INDUSTRY

NCT04708158 - Novaferon for COVID-19 Treatment Trial (NCTT-005) | Biotech Hunter | Biotech Hunter